


PATENT

I hereby certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

November 14, 2006  
Date 

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Grace Jung et al.  
Int'l Application No. : PCT/US2003/034655  
U.S. Application No. : 10/555,364  
Int'l Filing Date : October 31, 2003  
For : AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES  
THEREOF

Docket No. : 480102.411USPC  
Date : November 14, 2006

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Commissioner for Patents:

In accordance with 37 CFR 1.56 and 1.97 through 1.98, applicants wish to make known to the U.S. Patent and Trademark Office the references set forth on the attached Information Disclosure Statement. Copies of cited U.S. patents and published patent applications are not required and accordingly have not been provided. Copies of any other cited references are enclosed. As to any reference cited, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 CFR 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants'


duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Applicants believe this Information Disclosure Statement has been timely filed, however, the Director is authorized to charge any fee due by way of this Information Disclosure Statement to our Deposit Account No. 19-1090.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC



---

Emily W. Wagner

Registration No. 50,922

EWV:ljt

Enclosures:

Transmittal Letter  
Information Disclosure Statement  
Cited References (160)

701 Fifth Avenue, Suite 5400  
Seattle, Washington 98104  
Phone: (206) 622-4900  
Fax: (206) 682-6031

\860072

<b>U.S. DEPARTMENT OF COMMERCE</b> <b>PATENT AND TRADEMARK OFFICE</b>  <b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	480102.411USPC	10/555,364
	APPLICANTS	
	Grace Jung et al.	
	INT'L FILING DATE	GROUP ART UNIT
	October 31, 2003	N/A

### U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	2,954,380	9/27/60	Shapiro et al.			
	AB	3,218,328	11/16/95	Shapiro et al.			
	AC	4,145,435	3/20/79	Szmuszkovicz			
	AD	4,179,501	12/18/79	Szmuszkovicz			
	AE	4,598,087	7/1/86	Horwell			
	AF	4,656,182	4/7/87	Horwell			
	AG	4,663,343	5/5/87	Horwell et al.			
	AH	4,855,316	8/8/89	Horwell et al.			
	AI	4,880,800	11/14/89	Wallis			
	AJ	4,906,655	3/6/90	Horwell et al.			

### FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AK	CA 1234808	4/5/88	Canada		
	AL	CA 1235122	4/12/88	Canada		
	AM	CA 2004575	6/6/90	Canada		
	AN	CA 2008391	12/23/97	Canada		
	AO	CA 2058502	6/28/93	Canada		

### OTHER ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	AP	Adcock, J.J. et al., (2003) "RSD931, a novel anti-tussive agent acting on airway sensory nerves" Br J Pharm, 138:407-416.
	AQ	Allen I. Bain et al., "Ion Channel Modulating Compounds and Uses Thereof," U.S. Patent Application 11/450,921, filed June 9, 2006, pending.
	AR	Altria, Kevin D. et al., (2001) "Capillary Electrophoresis as a Routine Analytical Tool in Pharmaceutical Analysis" LCGC 19(9): 972-985.

EXAMINER	DATE CONSIDERED
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant(s).	

<b>U.S. DEPARTMENT OF COMMERCE</b> <b>PATENT AND TRADEMARK OFFICE</b>  <b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	480102.411USPC	10/555,364
	APPLICANTS	
	Grace Jung et al.	
	INT'L FILING DATE	GROUP ART UNIT
	October 31, 2003	N/A

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA	5,019,588	5/28/91	Horwell et al.			
	BB	5,051,428	9/24/91	Horwell et al.			
	BC	5,059,620	10/22/91	Stout et al.			
	BD	5,492,825	2/20/96	Jan et al.			
	BE	5,506,257	4/9/96	MacLeod et al.			
	BF	5,637,583	6/10/97	MacLeod et al.			
	BG	5,670,335	9/23/97	Jan et al.			
	BH	5,728,535	3/17/98	Lester et al.			
	BI	5,734,021	3/31/98	Lester et al.			
	BJ	5,750,537	5/12/98	Nomura et al.			

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	BK	CA 2132841	3/20/01	Canada		
	BL	CA 2172513	3/30/95	Canada		
	BM	CA 2244209 A1	07/31/97	Canada		
	BN	CA 2268590	10/12/00	Canada		
	BO	CA 2289055	1/28/99	Canada		

**OTHER ART** (Including Author, Title, Date, Pertinent Pages, Etc.)

	BP	Alzheimer's Disease Information Page [online], [retrieved on 10/03/2006]. Retrieved from the Internet, URL; < <a href="http://www.ninds.nih.gov/disorders/alsheimersdisease/alzheimersdisease.htm">http://www.ninds.nih.gov/disorders/alsheimersdisease/alzheimersdisease.htm</a> >
	BQ	Amin et al., (1996) "RPR 101821, a New Potent Cholesterol-lowering Agent: Inhibition of Squalene Synthase and 7-Dehydrocholesterol Reductase", Naunyn-Schmiedeberg's Arch Pharmacol 353:233-240.

EXAMINER	DATE CONSIDERED
----------	-----------------

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

<b>U.S. DEPARTMENT OF COMMERCE</b> <b>PATENT AND TRADEMARK OFFICE</b>  <b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	480102.411USPC	10/555,364
	APPLICANTS	
	Grace Jung et al.	
	INT'L FILING DATE	GROUP ART UNIT
	October 31, 2003	N/A

### U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	CA	5,817,698	10/6/98	Brown et al.			
	CB	5,885,984	3/23/99	MacLeod et al.			
	CC	6,174,879	1/16/01	MacLeod et al.			
	CD	6,180,632	1/30/01	Myers et al.			
	CE	6,210,809	04/03/01	Okutomi et al.	428	546	
	CF	6,214,810	04/10/01	Fermini et al.	514	75	
	CG	6,451,819	09/17/02	Alanine et al.	514	326	
	CH	6,521,619	02/18/03	Link et al.	514	237.2	
	CI	6,649,603	11/18/03	Lum	514	210.01	
	CJ	6,979,685	12/27/05	Beatch et al.	514	231.2	

### FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	CK	DE 2 259 260	6/6/74	Germany		X
	CL	DE 2 658 401	7/6/78	Germany (English Abstract)		X
	CM	DE 3 517 901	12/12/85	Germany (English Abstract)		X
	CN	EP 147085 B1	7/3/85	EPO		
	CO	EP 222533 A1	5/20/87	EPO		

### OTHER ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	CP	Bain et al., (1997) "Better Antiarrhythmics? Development of Antiarrhythmic Drugs Selective for Ischaemia-Dependent Arrhythmias", Drug Development Research 42:198-210.
	CQ	Barret, T. D. et al., (1996) "Glibenclamide Possesses Transient, Ischaemia Selective Class III Antiarrhythmic Actions But does not Prevent Ischaemic Arrhythmias" BPS Proceedings 116P.
	CR	Barrett, T. D. et al., (1997) "A model of myocardial ischemia for the simultaneous assessment of electrophysiological changes and arrhythmias in intact rabbits" J Pharmacol Toxicol Methods, 37:27-36.

EXAMINER	DATE CONSIDERED
----------	-----------------

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

<b>U.S. DEPARTMENT OF COMMERCE</b> <b>PATENT AND TRADEMARK OFFICE</b>  <b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	480102.411USPC	10/555,364
	APPLICANTS	
	Grace Jung et al.	
	INT'L FILING DATE	GROUP ART UNIT
	October 31, 2003	N/A

### U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	DA	7,053,087	05/30/06	Beatch et al.	514	237.8	
	DB	7,057,053	06/06/06	Beatch et al.	548	541	
	DC	7,101,877	09/05/06	Bain et al.	514	231.2	
	DD	2005/0209307	09/22/05	Bain et al.	514	1	
	DE	2005/0119315	06/02/05	Fedida et al.	514	355	
	DF	2005/0070552	03/31/05	Fedida et al.	514	255.06	
	DG	2005/0038256	02/17/05	Barrett et al.	546	236	
	DH	2005/0026993	02/03/05	Beatch et al.	514	424	
	DI	2006/0189677	08/24/06	Beatch et al.	514	424	
	DJ	2006/0247300	11/02/06	Beatch et al.	514	424	

### FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	DK	EP 372466 A2	6/13/90	EPO		
	DL	EP 380063 B1	8/1/90	EPO		
	DM	EP 552386 A1	7/28/93	EPO		
	DN	EP 720605 B1	12/19/01	EPO		
	DO	HU 215963 B	2/28/98	Hungary		X

### OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	DP	Barrett, T.D. (2000) "Ischaemia selectivity confers efficacy for suppression of ischaemia-induced arrhythmias in rats" Eur J Pharm, 398:365-374.
	DQ	Barrett, T.D. et al., (1996) "Atypical Dose Response curves for Antiarrhythmic Drugs" BPS Proceedings 115P.
	DR	Barrett, Terrance D. (1997) "Ischemia Selective Electrophysiological and antiarrhythmic actions of RSD1019 in ischemic cardiac tissue" J Mol Cell Cardiol, pp 197.

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

<b>U.S. DEPARTMENT OF COMMERCE</b> <b>PATENT AND TRADEMARK OFFICE</b>  <b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	480102.411USPC	10/555,364
	APPLICANTS Grace Jung et al.	
	INT'L FILING DATE	GROUP ART UNIT
	October 31, 2003	N/A

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
EA						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	EB	JP 02-270864	11/5/90	JP (English Abstract)		X
	EC	WO 93/19056	9/30/93	WIPO		
	ED	WO 94/07843	4/14/94	WIPO		
	EE	WO 94/14435	7/7/94	WIPO		
	EF	WO 95/08544	3/30/95	WIPO		
	EG	WO 95/28155	10/26/95	WIPO		
	EH	WO 96/18615	6/20/96	WIPO		
	EI	WO 96/23894	8/8/96	WIPO		
	EJ	WO 97/32857	9/12/97	WIPO		
	EK	WO 97/49680	12/31/97	WIPO		
	EL	WO 99/02159	1/21/99	WIPO		

**OTHER ART** (Including Author, Title, Date, Pertinent Pages, Etc.)

	EM	Barrett, Terrance D. et al., (2000) "RSD 1019 suppresses ischaemia-induced monophasic action potential shortening and arrhythmias in anaesthetized rabbits" Br J Pharm, 131:405-414.
	EN	Beatch et al., (2002) "RSD1235 Selectively Prolongs Atrial Refractoriness and Terminates AF in Dogs with Electrically Remodelled Atria", Pharmacologist, 44(2) (Supplement I), A15: XIV <sup>th</sup> World Congress of Pharmacology: Meeting Abstracts.
	EO	Beatch et al., (2002) "RSD1235 Selectively Prolongs Atrial Refractoriness and Terminates AF in Dogs with Electrically Remodeled Atria", (NASPE) North Amer. Soc. of Pacing & Electrophysiol. 24:698 (Abstract 702).
	EP	Beatch, G. et al., "Effect of a Novel Anti-tussive Compound CP1 Against Citric Acid Induced Cough in Guinea-Pigs" Proc West Pharmacol Soc, 2001 .
	EQ	Beatch, G. et al., "Electrophysiological Profile of RSD1235, A New Drug for Conversion of Atrial Fibrillation.

EXAMINER	DATE CONSIDERED
----------	-----------------

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

<b>U.S. DEPARTMENT OF COMMERCE</b> <b>PATENT AND TRADEMARK OFFICE</b>				ATTY. DOCKET NO. <b>480102.411USPC</b>		APPLICATION NO. <b>10/555,364</b>	
<b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)				APPLICANTS <b>Grace Jung et al.</b>			
				INT'L FILING DATE <b>October 31, 2003</b>		GROUP ART UNIT <b>N/A</b>	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	FA						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
					YES	NO	
	FB	WO 99/03468	1/28/99	WIPO			
	FC	WO 99/11252	3/11/99	WIPO			
	FD	WO 99/16431	4/8/99	WIPO			
	FE	WO 99/50205	10/7/99	WIPO			
	FF	WO 99/50225	10/7/99	WIPO			
	FG	WO 00/47547	8/17/00	WIPO			
	FH	WO 00/51981	9/8/00	WIPO			
	FI	WO 01/96335	12/20/01	WIPO			
	FJ	WO 03/105756	12/24/03	WIPO			
	FK	WO 2004/008103	01/22/04	WIPO			
	FL	WO 2004/098525	11/18/04	WIPO			
<b>OTHER ART</b> <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	FM	Beatch, G. et al., "RSD1235 Rapidly and Effectively Terminates Atrial Fibrillation" Abstract submission ESC Congress August 30-September 3, 2003, in Vienna, Austria.					
	FN	Beatch, G. N. et al., "RSD1235, A Novel Atrial-Selective Antiarrhythmic Drug, Shows Rapid and Extensive Oral Absorption in Man" 12 <sup>th</sup> International Congress on Cardiovascular Pharmacotherapy, May 7-10, 2003, Barcelona, Spain.					
	FO	Beatch, G. N. et al., (2002) "Ventricular Fibrillation, and Uncontrolled Arrhythmia Seeking New Targets" Drug Develop Res 55: 45-52.					
	FP	Beatch, G.N. et al., (1996) "Antihistamine-induced Ventricular Arrhythmias" BPS Proceedings 120P.					
	FQ	Beatch, G.N. et al., (1997) "Characterization of a Non-Human Primate Model of Drug-Induced Torsades De Pointes" Proc. West. Pharmacol. Soc., 40: 13-16.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant(s).							



<b>U.S. DEPARTMENT OF COMMERCE</b> <b>PATENT AND TRADEMARK OFFICE</b>  <b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	480102.411USPC	10/555,364
	APPLICANTS	
	Grace Jung et al.	
	INT'L FILING DATE	GROUP ART UNIT
	October 31, 2003	N/A

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
GA						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	GB	WO 2004/099137	11/18/04	WIPO		
	GC					
	GD					

**OTHER ART** (Including Author, Title, Date, Pertinent Pages, Etc.)

	GE	Bian et al., (1998)" Effects of K-opioid receptor stimulation in the heart and the involvement of protein kinase C" Brit. J. Pharmacol. 124:600-606.
	GF	Billman, (2003) "RSD-1235", Current Opinion Investigational Drugs 4(3):352-354.
	GG	Boiadjev et al., (1996) "pH-Sensitive Exciton Chirality Chromophore..Solvatochromic Effects on Circular Dichroism Spectra", Tetrahedron: Asymmetry 7(10):2825-2832.
	GH	Bowen et al., (1992)" Characterization of the enantiomers of cis-n-[2-(3,4-Dichlorophenyl)Ethyl]-N-Methyl-2-(1-Pyrrolidinyl)Cyclohexylamine (BD737 and BD738): Novel Compounds with High Affinity, Selectivity and Biological Efficacy at Sigma Receptors" J. Pharmacol. Exp. Ther. 262(1):32-40.
	GI	Cardiome Drug Effective for Heart Patients. Press Release September 3, 2002, 3 pages.
	GJ	Cardiome Pharma Completes Phase I Safety Study. New Release Transmitted By CNN Newswire, July 30, 2001. 2 pages.
	GK	Cardiome Pharma Corp. Healthcare (Underweight) Company Report December 12, 2002. 26 pages.
	GL	Cardiome Reports Dosing of First Patient in Pivotal Phase II Study. Press Release January 17, 2002. 3 pages.
	GM	Cardiome Reports Oral Absorption of RSD1235 in Humans. News Release via Canada Newswire (2002).3 pages.

EXAMINER	DATE CONSIDERED
----------	-----------------

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  <b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)				ATTY. DOCKET NO. <b>480102.411USPC</b>		APPLICATION NO. <b>10/555,364</b>	
				APPLICANTS <b>Grace Jung et al.</b>			
				INT'L FILING DATE <b>October 31, 2003</b>		GROUP ART UNIT <b>N/A</b>	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	HA						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION	
						YES	NO
	HB						
<b>OTHER ART</b> <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	HC	Clohs, L. et al., (2002) "Validation of a capillary electrophoresis assay for assessing the metabolic stability of verapamil in human liver microsomes" J Cap Elec & Microchip Tech. 007: 113-117.					
	HD	Clohs, Lilian "Capillary Electrophoresis And Its Applications In The Pharmaceutical Industry" Short Course: One Platform Fits Many Applications. CSC 2002 Short Course, 52 pages.					
	HE	Clohs, Lilian "Capillary Electrophoresis as an Analytical Tool in the Drug Discovery Process" Presentation CE Symposium, August, 2000, 40 pages.					
	HF	Clohs, Lilian "The Versatility of CE for Drug Pharmacokinetics and Metabolism Studies" Presentation CE Symposium, August, 2001, 46 pages.					
	HG	Clohs, Lilian (2001) "Pharmacokinetics profiling of new drug candidates: a key process in drug discovery" 4(1): 6.					
	HH	Clohs, Lilian et al., (2002) "CE Analysis of Propranolol in Human Serum Using Dynamic Capillary Coating" CE Currents: LCGC Europe, Reader Service 14, pp: 289-293.					
	HI	Clohs, Lilian. "Bio-Analytical Applications of Capillary Electrophoresis In A Drug Discovery Setting" CSC Seminar June 2002, 29 pages.					
	HJ	Clohs, Lilian. "CE and Drug Metabolism Studies: A Powerful Combination in Drug Discovery" CE Symposium Washington, DC, (August 2002), 31 pages.					
	HK	Crotti et al., (1998) "Regiochemical control of the ring-opening of epoxides by means of chelating processes Part 13 ...", Chemical Abstracts 129(17):662-663, abstract no. 216472k.					
	HL	Crotti et al., (1998) "Synthesis and Ring-Opening Reactions of the Diastereoisomeric <i>cis</i> - and <i>trans</i> -Epoxides Derived from 3-(Benzyloxy)cyclopentene and 2-(Benzyloxy)-2,5-dihydrofuran" Eur. J. Org. Chem. 8:1675-1686.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO. <b>480102.411USPC</b>		APPLICATION NO. <b>10/555,364</b>	
<b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)				APPLICANT'S <b>Grace Jung et al.</b>			
				INT'L FILING DATE <b>October 31, 2003</b>		GROUP ART UNIT <b>N/A</b>	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	IA						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION	
						YES	NO
	IB						
<b>OTHER ART</b> (Including Author, Title, Date, Pertinent Pages, Etc.)							
	IC	De Costa, Brian R. (1990) "Synthesis and Evaluation of N-Substituted <i>cis</i> -N-Methyl-2-(1-pyrrolidinyl)cyclohexylamines as High Affinity $\sigma$ Receptor Ligands. Identification of a New Class of Highly Potent and Selective $\sigma$ Receptor Probes" J Med Chem, 33:3100-3110.					
	ID	Doci, A. "Local Anesthetic Effects of Intradermal RSD921 In Healthy Subjects" in <i>Proceedings of the 100th Annual meeting of the American Society for Clinical Pharmacology and Therapeutics</i> , San Antonio, Texas, USA. March 18-20, 1999, 65(2): 177, February 1999. Abstract PIII-2.					
	IE	Duan, D. et al., (1993) "Potassium Channel Blocking Properties of Propafenone in Rabbit Atrial Myocytes" J Pharm Exp Ther 264(3): 1113-1123.					
	IF	Ezrin et al., (2002) "Safety and Pharmacokinetics of RSD1235, a Novel Atrial Fibrillation Converting Drug, in Health Volunteers", Abstracts: 11th Int. Congress Cardiovasc. Pharmacother. 16 Abstract P297.					
	IG	Ezrin, Alan M. et al., (2002) "A Dose-Ranging Study of RSD1235, A Novel Antiarrhythmic Agent, In Healthy Volunteers" Pharmacologist, 44(2) (Supplement I), A15: XIV <sup>th</sup> World Congress of Pharmacology: Meeting Abstracts.					
	IH	Fedida, D. et al., (2002) "Kv1.5 is an Important Component of Repolarizing K <sup>+</sup> Current in Canine Atrial Myocytes" Circulation Research Peer Review Plus Manuscript PDF, 38 pages.					
	II	Franciosi, Luigi G. et al., "Phase II Clinical Trial of RSD921 as a Local Anaesthetic in Patients Undergoing Venous Cannulation For Elective Treatment" in <i>Proceedings of the 28th Annual ACCP Meet Abstract 32</i> , pp 977, February 2000.					
	IJ	Franciosi, Sonia et al. (2001) "pH-dependent blocking actions of three novel antiarrhythmic compounds on K <sup>+</sup> and Na <sup>+</sup> currents in rat ventricular myocytes" Eur J Pharm, 425:95-107.					
	IK	Franqueza, L. et al., (1998) "Effects of propafenone and 5-hydroxy-propafenone on hKv1.5 channels" Br J Pharm 125:969-978.					
	IL	Friess et al., (1961) "Central Activity Evoked in the Cat by Cis-Trans Isomers of 1,2-Aminocyclohexanol Derivatives" Toxicol. Appl. Pharmacol. 3:638-653.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  <b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)				ATTY. DOCKET NO. <b>480102.411USPC</b>		APPLICATION NO. <b>10/555,364</b>	
				APPLICANTS <b>Grace Jung et al.</b>			
				INT'L FILING DATE <b>October 31, 2003</b>		GROUP ART UNIT <b>N/A</b>	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	JA						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION	
						YES	NO
	JB						
<b>OTHER ART</b> <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	JC	Grant, (1998) "Mechanisms of Atrial Fibrillation and Action of Drugs Used in its Management", Am J Cardiol 82:43N-49N.					
	JD	Gregory M. Beatch et al., "Aminocyclohexyl Ether Compounds and Uses Thereof," U.S. Patent Application 11/202,381, filed August 11, 2005, pending.					
	JE	Halfpenny, Paul R. (1990) "Highly Selective <i>k</i> -Opioid Analgesics. 3. Synthesis and Structure-Activity Relationships of Novel <i>N</i> -[2-(1-Pyrrolidinyl)4- or -5-substituted-cyclohexyl]arylacetamide Derivatives" J Med Chem, 33:286-291.					
	JF	Halfpenny, Paul R. et al., (1989) "Highly Selective <i>k</i> -Opioid Analgesics. 2. Synthesis and Structure-Activity Relationships of Novel <i>N</i> -[(2-Aminocyclohexyl)aryl]acetamide Derivatives" J Med Chem, 32:1620-1626.					
	JG	Hayes, E. S. et al., (1996) "RSD992 Enhances Erection and Copulation in Rats and Erection in Primates" Int J Impotence Res, pp 189, (Abstract P24).					
	JH	Hayes, ES. Et al., (1997) "Actions of Arylpiperazines on Corpus Cavernosum Smooth Muscle In Vitro" Asia Pac J Pharmacol, 12:97-103.					
	JI	Hayes, ES. et al., (1997) "Direct Actions of Arylpiperazines on Rabbit and Human Corpus Cavernosum Smooth Muscle <i>In Vitro</i> " Asia Pac J Pharmacol, Abstract S15.					
	JJ	Hesketh, J., et al., "Safety of RSD1235 in a rabbit purkinje fiber model", in <i>Proceedings of the XIVth World Congress of Phar. Meeting</i> , Abstract No. 22.12, 2002.					
	JK	Keefe, D. et al. (1981) "New Antiarrhythmic Drugs: Their Place in Therapy" Drugs 22:363-400.					
	JL	Kertesz, R. et al., "The Electrophysiological and Antiarrhythmic Actions of RSD Analogs of U50,488H in Rats" in <i>Proceedings of the West Pharmacol Soc.</i> 9 pages, 1994.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

<b>U.S. DEPARTMENT OF COMMERCE</b> <b>PATENT AND TRADEMARK OFFICE</b>  <b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	480102.411USPC	10/555,364
	APPLICANTS	
	Grace Jung et al.	
	INT'L FILING DATE	GROUP ART UNIT
	October 31, 2003	N/A

### U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
KA						

### FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
KB					

### OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

KC	Lang, C. C. et al., (2000) "Clinical Evaluation of RSD921 As a Local Anaesthetic in Patients Undergoing Venous Cannulation for Elective Treatment" Clin Pharm & Therapeutics, pp 142.
KD	Lewis et al., (1995) "Enzyme inhibition during the conversion of squalene to cholesterol", Steroids 60:475-483.
KE	Li, GR. et al., (1996) "Adrenergic Modulation of Ultrarapid Delayed Rectifier K <sup>+</sup> current in Human Atrial Myocytes" Circ. Res. 78:903-915.
KF	Malayev, A. A. et al., (1995) "Mechanism of Clofilium Block of the Human Kv1.5 Delayed Rectifier Potassium Channel" Mol Pharm 47:198-205.
KG	Martens et al., (1989) "Einfache Synthese neuer anellierter Pyrrole", J. Synth. Org. Chem. 12:965-967.
KH	Matyus et al., (1997) "Antiarrhythmic Agents: Current Status and Perspective", Medicinal Research Reviews 17(5):427-451.
KI	McLarnon, J. et al., (1996) "Mixed Block of K and Na Currents By KC8851, A Structural of Tedisamil <i>In Vitro</i> and <i>In Vivo</i> Studies" BPS Proceedings 114P.
KJ	Moorman et al., (1986) "pK <sub>a</sub> Does Not Predict pH Potentiation of Sodium Channel Blockade by Lidocaine and W6211 in Guinea Pig Ventricular Myocardium <sup>1</sup> ", The Journal of Pharmacology and Experimental Therapeutics 238(1):159-166.
KK	Morisawa et al., (1991) "Preparation of fluorocarbocycle nucleosides as antitumor agents", Chemical Abstracts 115(5):904-905, abstract no. 50215n.
KL	Nakahsima, H. et al., (2002) "Angiotensin II Type I Receptor Antagonist Prevents the Promotion of Atrial Fibrillation" PACE 24(Part II):698. Abstract 701.

EXAMINER	DATE CONSIDERED
----------	-----------------

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

<b>U.S. DEPARTMENT OF COMMERCE</b> <b>PATENT AND TRADEMARK OFFICE</b>  <b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	480102.411USPC	10/555,364
	APPLICANTS	
	Grace Jung et al.	
	INT'L FILING DATE	GROUP ART UNIT
	October 31, 2003	N/A

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
LA						

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
LB					

**OTHER ART** (Including Author, Title, Date, Pertinent Pages, Etc.)

LC	Nattel et al., (1998) "Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties", Cardiovascular Research 37:627-635.
LD	Nattel et al., (2001) "RSD1235: a novel antiarrhythmic agent with a unique electrophysiological profile that terminates AF in dogs", Eur. Heart J 22(Suppl):448 (Abstract P2362).
LE	Nattel, (1998) "Experimental evidence for proarrhythmic mechanisms of antiarrhythmic drugs", Cardiovascular Research 37:567-577.
LF	Nattel, S. et al., "The Role of Channel Opening in Transient Outward Current Block By Quinidine, Flecainide, and 4-Aminopyridine in Human Atrial Myocytes" K Channels II: Regulation and Block, Abstract No. Tu-Pos403, 1994.
LG	Nishi et al., (1985) "Studies on 2-Oxoquinoline Derivatives as Blood Platelet Aggregation Inhibitors. IV." Synthesis and Biological Activity of the Metabolites of 6-[4-(1-Cyclohexyl-1 H-5-tetrazolyl)butoxy]-2-oxo-1,2,3,4-tetrahydroquinoline (OPC-13013)", Chem. Pharm. Bull 33(3):1140-1147.
LH	Nortran Arrhythmia Drug Demonstrates Oral Bioavailability. New Release Transmitted By CNN Newswire, June 21, 2001. 2 pages.
LI	Orth et al., (1978) "Cyclopentane-1-amines" Chemical Abstracts 89(15):555, abstract no. 129113f.
LJ	Orth, Peter et al., "The Novel AF Conversion Agent RSD1235 Preferentially Blocks a Late Component of the Human Heart (h1) Na <sup>+</sup> Current Active During Repolarization" EP abstracts October 2003.
LK	Plouvier, B., "Synthesis and Structure Activity Relationships of a Series of 2-Aminocyclohexyl ..as Potential Ischaemia Selective Ventricular Antiarrhythmics BMPS 994.
LL	Pugsley and Goldin, "Molecular analysis of the Na <sup>+</sup> channel blocking actions of the novel class I antiarrhythmic" Br J Pharm, 127:9-18, 1999.

EXAMINER	DATE CONSIDERED
----------	-----------------

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

<b>U.S. DEPARTMENT OF COMMERCE</b> <b>PATENT AND TRADEMARK OFFICE</b>  <b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	480102.411USPC	10/555,364
	APPLICANTS Grace Jung et al.	
	INT'L FILING DATE	GROUP ART UNIT
	October 31, 2003	N/A

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
MA						

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
MB					

**OTHER ART** (Including Author, Title, Date, Pertinent Pages, Etc.)

MC	Pugsley, M.K. et al., "A Characterization of the Antiarrhythmic and Electrophysiological Properties of RSD992, A Novel Arylpiperazine Drug" (XIVth World Congress of Pharmacology: Meeting Abstract 22.8.
MD	Pugsley, M.K. et al., "Electropharmacology of two new class 1 agents" <i>Heart and Stroke Annual Conference</i> , p. 12, 1995.
ME	Pugsley, M.K. et al., (1998) "Sodium Channel-Blocking Properties of Spiradoline, a K Receptor Agonist, are Responsible for Its Antiarrhythmic Action in the Rat" <i>J Cardiovas Pharmacol</i> , 32:863-974.
MF	Pugsley, M.K. et al., (1999) "Are the arrhythmias due to myocardial ischaemia and infarction dependent upon the sympathetic system?" <i>Cardiol Res</i> , 43:830-831.
MG	Ribeiro, W. et al., (2001) "Determination of RSD921 in human plasma by high-performance liquid chromatography-tandem mass spectrometry using tri-deuterated RSD921 as internal standard: application to a phase I clinical trial" <i>J Mass Spectrom</i> , 36:1133-1139.
MH	Rich, T. C. et al. "Quinidine Block of the Human Cardiac hKv1.5 Channel in Inside-Out Patches" <i>K Channels II: Regulation and Block</i> , Abstract No. Tu-Pos404, 1999.
MI	Roden et al., (1996) "The Cardiac Ion Channels: Relevance to Management of Arrhythmias", <i>Annu. Rev. Med.</i> 47:135-148.
MJ	Roy, D. et al., (2003) "RSD1235 Rapidly and Effectively Terminates Atrial Fibrillation" <i>Eur Heart J</i> .
MK	Rynbrandt, Ronald H, et al., (1971) "Cis-1-[2-(p-Anisidinomethyl)cyclohexyl]piperidine and Related Compounds Oral Hypoglycemic Agents" <i>J Med Chem</i> , 14(10): 985-987.
ML	Sanguinetti M. C. (1992) "Modulation of Potassium Channels by Antiarrhythmic and Antihypertensive Drugs" <i>Hypertension</i> 19(3):228-236.

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

<b>U.S. DEPARTMENT OF COMMERCE</b> <b>PATENT AND TRADEMARK OFFICE</b>  <b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	480102.411USPC	10/555,364
	APPLICANTS	
	Grace Jung et al.	
	INT'L FILING DATE	GROUP ART UNIT
	October 31, 2003	N/A

### U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
NA						

### FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
NB					

### OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

NC	Singh, (1998) "Antiarrhythmic Drugs: A Reorientation in Light of Recent Developments in the Control of Disorders of Rhythm", Am J Cardiol 81(6A):3D-13D.
ND	Singh, (2003) "Atrial Fibrillation: Epidemiologic Considerations and Rationale for Conversion and Maintenance of Sinus Rhythm", J. Cardiovasc. Pharmacol. Ther. 8(Suppl 1):S13-S26.
NE	Snyders, D. J. et al., (1993) "A Rapidly Activating and Slowly Inactivating Potassium Channel Cloned from Human Heart" J. Gen. Physiol. 101:513-542.
NF	Snyders, D. J. et al., (1995) "Determinants of Antiarrhythmic Drug Action Electrostatic and Hydrophobic Components of Block of the Human Cardiac hKv1.5 Channel" Circ. Res. 77 (3):575-583.
NG	Srilatha, B. et al., (1997) "Alterations in Rabbit Corpus Cavernosal Pharmacology By High Cholesterol Diet" Asia Pac J Pharmacol, Abstract S15.
NH	Steinbeck, G. (1992) "Proarrhythmische Wirkungen von Antiarrhythmika-theoretische und klinische Aspekte" Z Kardiol. 81: Suppl. 4,139-143.
NI	Stevenson, W.G. et al., "Atrial Fibrillation and Heart Failure – Five More Years," <i>New England Journal of Medicine</i> 351(23): 2437-2440, December 2, 2004.
NJ	Tong, V. et al., (2001) "Determination of an aryether antiarrhythmic and its N-dealkyl metabolite in rat plasma and hepatic microsomal incubates using liquid chromatography-tandem mass spectrometry" J Chromatog B., 759:256-266.
NK	Valenzuela, C. et al. (1997) "Comparative effects of nonsedating histamine H <sub>1</sub> receptor antagonists, ebastine and terfenadine, on human Kv1.5 channels" Eur J Pharm 326:257-263.
NL	Valenzuela, C. et al., (1997) "Effects of Ropivacaine on a Potassium Channel (hKv1.5) Cloned from Human Ventricle" Anesthesiology 86:718-728.

EXAMINER	DATE CONSIDERED
----------	-----------------

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).



<b>U.S. DEPARTMENT OF COMMERCE</b> <b>PATENT AND TRADEMARK OFFICE</b>  <b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	480102.411USPC	10/555,364
	APPLICANTS	
	Grace Jung et al.	
	INT'L FILING DATE	GROUP ART UNIT
	October 31, 2003	N/A

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
OA						

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
OB					

**OTHER ART** *(Including Author, Title, Date, Pertinent Pages, Etc.)*

OC	Walker, J. A. (2002) "Antiarrhythmic Drug Development - Illusion and Disillusion" Drug Develop Res 55:1-2.
OD	Walker, M. L. et al., "Determination of an arylacetamide antiarrhythmic in rat blood and tissues using reversed-phase high-performance liquid chromatography" J Chromatog B., 675:257-263, 1996.
OE	Walker, M.L. et al., (1996) "Increased Electrophysiological Activity in Raised K and low pH Improves Antiarrhythmic efficacy for a group of morpholinocyclohexyl Derivatives" BPS Proceedings 118P.
OF	Walker, Michael J.A. and Guppy, Leon J. "Targeting Ischemic Ventricular Arrhythmias" Cardiac Drug Development, pp 175-201, 2002-2003.
OG	Wang, Z. et al., (1995) "Effects of Flecainide, Quinidine, and 4-Aminopyridine on Transient Outward and Ultrarapid Delayed Rectifier Currents in Human Atrial Myocytes <sup>1</sup> " J Pharm Exp Ther., 272(1):184-196.
OH	Wang, Z. et al., (1993) "Sustained Depolarization-Induced Outward Current in Human Atrial Myocytes" Circ. Res. 73:1061-1076.
OI	Wat, J.Y.K. et al., "Effects of Arylbenzacetamides on Neuromuscular Preparation" Proc West Pharmacol Soc 19, 1994.
OJ	Wolf, et al. (1998) "Impact of Atrial Fibrillation on Mortality Stroke, and Medical Costs" Arch Intern Med 158: 229-234.
OK	Wong, Judy et al., "Protein Binding Study of AA5, a New Antiarrhythmic Drug" Poster Conference August, 2000.
OL	Wong, L. et al., "Capillary Electrophoresis Assay to Assess In Vitro Metabolic Stability of Novel Compounds in Human Liver Microsomes," AAPS Poster, October 2001.

EXAMINER	DATE CONSIDERED
----------	-----------------

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

<b>U.S. DEPARTMENT OF COMMERCE</b> <b>PATENT AND TRADEMARK OFFICE</b>				ATTY. DOCKET NO. <b>480102.411USPC</b>		APPLICATION NO. <b>10/555,364</b>	
<b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)				APPLICANTS <b>Grace Jung et al.</b>			
				INT'L FILING DATE <b>October 31, 2003</b>		GROUP ART UNIT <b>N/A</b>	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	PA						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION	
						YES	NO
	PB						
<b>OTHER ART</b> <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	PC	Yeola, S. W. et al., (1996) "Molecular Analysis of a Binding Site for Quinidine in a Human Cardiac Delayed Rectifier K <sup>+</sup> Channel" Circ. Res. 78(6): 1105-1114.					
	PD	Yong, S.L. et al., (1997) "Low pKa Predicts Antiarrhythmic Efficacy in a Series of Aminocyclohexyl Esters" J Mol Cell Cardiol.					
	PE	Yong et al., (1999) "RSD1000: A novel antiarrhythmic agent with increased potency under acidic and high-potassium conditions" J. Pharm. Exp. Ther. 289(1):236-244.					
	PF	Yong, S.L. et al., (1996) "RSD1000: A Novel Antiarrhythmic Agent with an Improved Therapeutic Index" BPS Proceedings 119P.					
	PG	Yong, S.L. et al., (1996) "SAR Evidence that Antiarrhythmic Activity is Unrelated to Opioid Kappa Agonist Activity" BPS Proceedings 117P.					
	PH	Zhang et al., (1997) "Inhibition of [ <sup>3</sup> H]-U69593 binding and the cardiac effects of U50, 488H by calcium channel blockers in the rat heart" Brit. J. Pharmacol. 120:827-832.					
	PI	Zolotoy, Alexander B. et al., (2003) "Physicochemical Determinants for Drug Induced Blockade of HERG Potassium Channels: Effect of Charge and Charge Shielding" Curr Med Chem 1(3): 1-17.					
	PJ						
	PK						
	PL						
	PM						
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							